Ignite Creation Date:
2024-05-05 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00332319
Status:
TERMINATED
Last Update Posted:
2015-04-17
First Post:
2006-05-30
Brief Title:
Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
See Detailed Description
Status:
TERMINATED
Status Verified Date:
2011-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a two-part study in which Part A will assess the effects of GW679769 after 1 dose on the function of the nerves that supply the bladder The technique for measuring the nerves function is called Neurometry Part B will assess the effect of repeat doses of GW679769 on the bladder nerve function Part B will also assess the effects of the drug on overactive bladder symptoms using a three-day patient diary
Detailed Description:
A randomized double-blind placebo-controlled study to evaluate the effects of GW679769 on Current Perception Threshold CPT following a single 150 mg dose Part A and to evaluate the effect of CPT and symptoms of overactive bladder following 28 days of repeat dosing with 120 mg GW679769 administered once daily Part B in patients with neurogenic bladder due to incomplete spinal cord injury
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None